Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





2017 State and City TB Report										Related Pages
										Return to Main Menu
Incidence [3]
Elimination of TB is defined as reducing TB disease incidence in the United States to less than 1 case per million persons per year. Therefore, measuring the number of new cases occurring each year remains the best overall indicator of progress toward TB elimination. In 2017, overall TB incidence in the United States was 2.8 TB cases (including U.S.-born and non-U.S.–born persons) per 100,000 persons (28 per million). Overall, TB incidence slightly declined from 2016 to 2017; however, the nation has not yet achieved the 2020 national target of <1.4 TB cases per 100,000 (Figure 1image icon and Figure 2image icon).This map shows states and cities color coded into one of 3 categories based on TB incidence: those that were at or below the 2020 target of 1.4 TB cases/100,000 persons (Montana, Wyoming, Vermont, Idaho, Wisconsin, West Virginia, Utah, Kansas, Pennsylvania, Maine, Nebraska, Rhode Island, Ohio, Michigan, Oklahoma, New Hampshire, and Missouri), those that were above the 2020 target of 1.4, but were at or below the national average of 2.8 (Kentucky, Iowa, Colorado, Indiana, Delaware, South Dakota, Oregon, New York, Connecticut, New Mexico, Mississippi, North Dakota, Tennessee, South Carolina, Illinois, North Carolina, Virginia, Alabama, Florida, Nevada, Arizona, Washington, Georgia, and  Arkansas) and those that were above the national average of 2.8 (Louisiana, Massachusetts, New Jersey, Minnesota, Maryland, Texas, Baltimore, Chicago, California, Philadelphia, District of Columbia, Los Angeles, San Diego, New York City, Alaska, Houston, Hawaii, and San Francisco).resize iconView LargerCloseThis map shows states and cities color coded into one of 3 categories based on TB incidence: those that were at or below the 2020 target of 1.4 TB cases/100,000 persons (Montana, Wyoming, Vermont, Idaho, Wisconsin, West Virginia, Utah, Kansas, Pennsylvania, Maine, Nebraska, Rhode Island, Ohio, Michigan, Oklahoma, New Hampshire, and Missouri), those that were above the 2020 target of 1.4, but were at or below the national average of 2.8 (Kentucky, Iowa, Colorado, Indiana, Delaware, South Dakota, Oregon, New York, Connecticut, New Mexico, Mississippi, North Dakota, Tennessee, South Carolina, Illinois, North Carolina, Virginia, Alabama, Florida, Nevada, Arizona, Washington, Georgia, and  Arkansas) and those that were above the national average of 2.8 (Louisiana, Massachusetts, New Jersey, Minnesota, Maryland, Texas, Baltimore, Chicago, California, Philadelphia, District of Columbia, Los Angeles, San Diego, New York City, Alaska, Houston, Hawaii, and San Francisco).download iconDownload Imageimage icon[JPG, NAN ]This horizontal bar graph shows individual state and city TB incidence per 100,000 persons. States and cities are categorized into 3 groups based on numbers of TB cases reported in 2017. Within each group states and cities are ordered by increasing incidence and color coded by whether or not they met the 2020 national target (1.4), were between the 2020 target and national average (2.8), or had incidence above the national average. Among states/cities that reported 1-53 TB cases in 2017, incidences ranged from 0.3 in Wyoming to 7.2 in Alaska. Montana, Wyoming, Vermont, Idaho, Wisconsin, West Virginia, Utah, Kansas, Maine, Nebraska, Rhode Island, and New Hampshire had incidences at or below the 2020 target; Iowa, Delaware, South Dakota, New Mexico, Mississippi, North Dakota had incidences that were above the 2020 target, but were at or below the national average; Baltimore, the District of Columbia, and Alaska had incidences that were above the national average. Among states/cities that reported 54-140 TB cases in 2017, incidences ranged from 1.0 in Pennsylvania to 12.1 in San Francisco. Pennsylvania, Michigan, and Oklahoma, and Missouri had incidences at or below the 2020 target; Kentucky, Colorado, Indiana, Oregon, Connecticut, Tennessee, South Carolina, Alabama, Nevada, and Arkansas had incidences that were above the 2020 target, but were at or below the national average; Louisiana, Chicago, Philadelphia, Hawaii, and San Francisco had incidences that were above the national average. Among states/cities that reported 41 or more TB cases in 2017, incidence ranged from 1.3 in Ohio to 8.1 in Houston. Ohio had an incidence at or below the 2020 target; New York, Illinois, North Carolina, Virginia, Florida, Arizona, Washington, and Georgia had incidences that were above the 2020 target, but were at or below the national average; Massachusetts, New Jersey, Minnesota, Maryland, Texas, California, Los Angeles, San Diego, New York City, and Houston had incidences that were above the national average.resize iconView LargerCloseThis horizontal bar graph shows individual state and city TB incidence per 100,000 persons. States and cities are categorized into 3 groups based on numbers of TB cases reported in 2017. Within each group states and cities are ordered by increasing incidence and color coded by whether or not they met the 2020 national target (1.4), were between the 2020 target and national average (2.8), or had incidence above the national average. Among states/cities that reported 1-53 TB cases in 2017, incidences ranged from 0.3 in Wyoming to 7.2 in Alaska. Montana, Wyoming, Vermont, Idaho, Wisconsin, West Virginia, Utah, Kansas, Maine, Nebraska, Rhode Island, and New Hampshire had incidences at or below the 2020 target; Iowa, Delaware, South Dakota, New Mexico, Mississippi, North Dakota had incidences that were above the 2020 target, but were at or below the national average; Baltimore, the District of Columbia, and Alaska had incidences that were above the national average. Among states/cities that reported 54-140 TB cases in 2017, incidences ranged from 1.0 in Pennsylvania to 12.1 in San Francisco. Pennsylvania, Michigan, and Oklahoma, and Missouri had incidences at or below the 2020 target; Kentucky, Colorado, Indiana, Oregon, Connecticut, Tennessee, South Carolina, Alabama, Nevada, and Arkansas had incidences that were above the 2020 target, but were at or below the national average; Louisiana, Chicago, Philadelphia, Hawaii, and San Francisco had incidences that were above the national average. Among states/cities that reported 41 or more TB cases in 2017, incidence ranged from 1.3 in Ohio to 8.1 in Houston. Ohio had an incidence at or below the 2020 target; New York, Illinois, North Carolina, Virginia, Florida, Arizona, Washington, and Georgia had incidences that were above the 2020 target, but were at or below the national average; Massachusetts, New Jersey, Minnesota, Maryland, Texas, California, Los Angeles, San Diego, New York City, and Houston had incidences that were above the national average.download iconDownload Imageimage icon[JPG, NAN ]This map shows states and cities color coded into one of 3 categories based on TB incidence among U.S.-born persons: those that were at or below the 2020 target of 0.4 TB cases/100,000 U.S.-born persons (Rhode Island, Idaho, Maine, Vermont, Nebraska, Wisconsin, Utah, Iowa, Montana, New York, Pennsylvania, Kansas, New Mexico, Connecticut, Ohio, Colorado, and Indiana), those that were above the 2020 target of 0.4, but were at or below the national average of 1.0 (New Hampshire, Massachusetts, Virginia, West Virginia, Oregon, Michigan, Minnesota, Illinois, Washington, Missouri, Nevada, Maryland, New Jersey, Kentucky, Oklahoma, Arizona, South Dakota, North Dakota, North Carolina, and Delaware) and those that were above the national average of 1.0 (Tennessee, California, Los Angeles, Florida, Hawaii, San Francisco, South Carolina, Georgia, Mississippi, New York City, Texas, Philadelphia, Arkansas, Chicago, Louisiana, District of Columbia, Alabama, Baltimore, San Diego, Houston, and Alaska).  Wyoming did not report any TB cases among U.S.-born persons.resize iconView LargerCloseThis map shows states and cities color coded into one of 3 categories based on TB incidence among U.S.-born persons: those that were at or below the 2020 target of 0.4 TB cases/100,000 U.S.-born persons (Rhode Island, Idaho, Maine, Vermont, Nebraska, Wisconsin, Utah, Iowa, Montana, New York, Pennsylvania, Kansas, New Mexico, Connecticut, Ohio, Colorado, and Indiana), those that were above the 2020 target of 0.4, but were at or below the national average of 1.0 (New Hampshire, Massachusetts, Virginia, West Virginia, Oregon, Michigan, Minnesota, Illinois, Washington, Missouri, Nevada, Maryland, New Jersey, Kentucky, Oklahoma, Arizona, South Dakota, North Dakota, North Carolina, and Delaware) and those that were above the national average of 1.0 (Tennessee, California, Los Angeles, Florida, Hawaii, San Francisco, South Carolina, Georgia, Mississippi, New York City, Texas, Philadelphia, Arkansas, Chicago, Louisiana, District of Columbia, Alabama, Baltimore, San Diego, Houston, and Alaska).  Wyoming did not report any TB cases among U.S.-born persons.download iconDownload Imageimage icon[JPG, NAN ]This horizontal bar graph shows individual state and city TB incidence per 100,000 U.S.-born persons.  States and cities are categorized into 3 groups based on numbers of TB cases reported in 2017.  Within each group states and cities are ordered by increasing incidence and color coded by whether or not they met the 2020 national target (0.4), were between the 2020 target and national average (1.0), or had incidence above the national average.  Among states/cities that reported 1-53 TB cases in 2017, incidence among U.S.-born persons ranged from 0.1 in Rhode Island to 5.6 in Alaska.  Rhode Island, Idaho, Maine, Vermont, Nebraska, Wisconsin, Utah, Iowa, Montana, Kansas, and New Mexico had incidences at or below the 2020 target; New Hampshire, West Virginia, South Dakota, North Dakota, and Delaware had incidences that were above the 2020 target, but were at or below the national average; Mississippi, District of Columbia, Baltimore, and Alaska had incidences that were above the national average.   Among states/cities that reported 54-140 TB cases in 2017, incidence among U.S.-born persons ranged from 0.3 in Pennsylvania to 2.0 in Alabama.  Pennsylvania, Connecticut, Colorado, and Indiana had incidences at or below the 2020 target; Oregon, Michigan, Missouri, Nevada, Kentucky, Oklahoma, Tennessee, Hawaii, and San Francisco had incidences that were above the 2020 target, but were at or below the national average; South Carolina, Philadelphia, Arkansas, Chicago, and Alabama had incidences that were above the national average.  Among states/cities that reported 141 or more TB cases in 2017, incidence among U.S.-born persons ranged from 0.3 in New York to 4.0 in Houston.  New York and Ohio had incidences at or below the 2020 target; Massachusetts, Virginia, Minnesota, Illinois, Washington, Maryland, New Jersey, Arizona, and North Carolina had incidences that were above the 2020 target, but were at or below the national average; California, Los Angeles, Florida, Georgia, New York City, Texas, Louisiana, San Diego, and HoThis map shows states and cities color coded into one of 3 categories based on TB incidence among non-U.S.–born persons: those that were at or below the 2020 target of 11.1 TB cases/100,000 non-U.S.–born persons (Delaware, Vermont, Florida, Utah, Idaho, Rhode Island, Connecticut, Wyoming, Kansas, Nevada, and Oklahoma), those that were above the 2020 target of 11.1, but were at or below the national average of 14.4 (New Jersey, Colorado, Michigan, Nebraska, New York, Oregon, Illinois, Wisconsin, Pennsylvania, South Carolina, Los Angeles, Texas, Alabama, Mississippi, Arizona, North Carolina, and Chicago) and those that were above the national average of 14.4 (Georgia, New Hampshire, New Mexico, Washington, California, Massachusetts, Virginia, New York City, Maryland, Tennessee, Missouri, Houston, Kentucky, South Dakota, Ohio, Indiana, North Dakota, Philadelphia, Arkansas, San Diego, District of Columbia, Baltimore, West Virginia, Iowa, Maine, Alaska, Louisiana, Minnesota, San Francisco, and Hawaii). Montana did not report any TB cases among non-U.S.–born persons.resize iconView LargerCloseThis map shows states and cities color coded into one of 3 categories based on TB incidence among non-U.S.–born persons: those that were at or below the 2020 target of 11.1 TB cases/100,000 non-U.S.–born persons (Delaware, Vermont, Florida, Utah, Idaho, Rhode Island, Connecticut, Wyoming, Kansas, Nevada, and Oklahoma), those that were above the 2020 target of 11.1, but were at or below the national average of 14.4 (New Jersey, Colorado, Michigan, Nebraska, New York, Oregon, Illinois, Wisconsin, Pennsylvania, South Carolina, Los Angeles, Texas, Alabama, Mississippi, Arizona, North Carolina, and Chicago) and those that were above the national average of 14.4 (Georgia, New Hampshire, New Mexico, Washington, California, Massachusetts, Virginia, New York City, Maryland, Tennessee, Missouri, Houston, Kentucky, South Dakota, Ohio, Indiana, North Dakota, Philadelphia, Arkansas, San Diego, District of Columbia, Baltimore, West Virginia, Iowa, Maine, Alaska, Louisiana, Minnesota, San Francisco, and Hawaii). Montana did not report any TB cases among non-U.S.–born persons.download iconDownload Imageimage icon[JPG, NAN ]This horizontal bar graph shows individual state and city TB incidence per 100,000 non-U.S.–born persons. States and cities are categorized into 3 groups based on numbers of TB cases reported in 2017. Within each group states and cities are ordered by increasing incidence and color coded by whether or not they met the 2020 national target (11.1), were between the 2020 target and national average (14.4), or had incidence above the national average. Among states/cities that reported 1-53 TB cases in 2017, incidence among non-U.S.–born persons ranged from 6.4 in Delaware to 26.5 in Alaska. Delaware, Vermont, Utah, Idaho, Rhode Island, Wyoming, and Kansas had incidences at or below the 2020 target; Nebraska, Wisconsin, and Mississippi had incidences that were above the 2020 target, but were at or below the national average; New Hampshire, New Mexico, South Dakota, North Dakota, District of Columbia, Baltimore, West Virginia, Iowa, Maine, and Alaska had incidences that were above the national average. Among states/cities that reported 54-140 TB cases in 2017, incidences among non-U.S.–born persons ranged from 9.7 in Connecticut to 38.6 in Hawaii. Connecticut, Nevada, and Oklahoma had incidences at or below the 2020 target; Colorado, Michigan, Oregon, Pennsylvania, South Carolina, and Alabama had incidences that were above the 2020 target, but were at or below the national average; Chicago, Tennessee, Missouri, Kentucky, Indiana, Philadelphia, Arkansas, Louisiana, San Francisco, and Hawaii had incidences that were above the national average. Among states/cities that reported 141 or more TB cases in 2017, incidence among non-U.S.–born persons ranged from 7.4 in Florida to 30.5 in Minnesota. Florida had an incidence at or below the 2020 target; New Jersey, New York, Illinois, Los Angeles, Texas, Arizona, and North Carolina had incidences that were above the 2020 target, but were at or below the national average; Georgia, Washington, California, Massachusetts, Virginia, New York City, Maryland, Houston, Ohio, SanThis map shows states and cities color coded into one of 3 categories based on TB incidence among U.S.-born non-Hispanic black or African American persons: those that were at or below the 2020 target of 1.5 TB cases/100,000 U.S.-born non-Hispanic black or African American persons (Indiana, Pennsylvania, Maryland, Virginia, Connecticut, Arizona, Kentucky, Nevada, Kansas, Ohio, New York, West Virginia, Illinois, Wisconsin, and Michigan), those that were above the 2020 target of 1.5, but were at or below the national average of 2.8 (New Jersey, Colorado, Oregon, Oklahoma, Missouri, North Carolina, Massachusetts, California, Philadelphia, and New York City), and those that were above the national average of 2.8 (Louisiana, Washington, Baltimore, New Mexico, Tennessee, Delaware, Mississippi, South Carolina, Arkansas, Georgia, Texas, District of Columbia, Alabama, Los Angeles, Florida, San Diego, Chicago, Alaska, Minnesota, New Hampshire, Houston, and San Francisco).  Montana, Vermont, Idaho, Rhode Island, Maine, North Dakota, South Dakota, Nebraska, Utah, Iowa, Hawaii, and Wyoming did not report any TB cases among U.S.-born non-Hispanic black or African American persons.resize iconView LargerCloseThis map shows states and cities color coded into one of 3 categories based on TB incidence among U.S.-born non-Hispanic black or African American persons: those that were at or below the 2020 target of 1.5 TB cases/100,000 U.S.-born non-Hispanic black or African American persons (Indiana, Pennsylvania, Maryland, Virginia, Connecticut, Arizona, Kentucky, Nevada, Kansas, Ohio, New York, West Virginia, Illinois, Wisconsin, and Michigan), those that were above the 2020 target of 1.5, but were at or below the national average of 2.8 (New Jersey, Colorado, Oregon, Oklahoma, Missouri, North Carolina, Massachusetts, California, Philadelphia, and New York City), and those that were above the national average of 2.8 (Louisiana, Washington, Baltimore, New Mexico, Tennessee, Delaware, Mississippi, South Carolina, Arkansas, Georgia, Texas, District of Columbia, Alabama, Los Angeles, Florida, San Diego, Chicago, Alaska, Minnesota, New Hampshire, Houston, and San Francisco).  Montana, Vermont, Idaho, Rhode Island, Maine, North Dakota, South Dakota, Nebraska, Utah, Iowa, Hawaii, and Wyoming did not report any TB cases among U.S.-born non-Hispanic black or African American persons.download iconDownload Imageimage icon[JPG, NAN ]This horizontal bar graph shows individual state and city TB incidence per 100,000 U.S.-born non-Hispanic black or African American persons.  States and cities are categorized into 3 groups based on numbers of TB cases reported in 2017.  Within each group states and cities are ordered by increasing incidence and color coded by whether or not they met the 2020 national target (1.5), were between the 2020 target and national average (2.8), or had incidence above the national average.  Among states/cities that reported 1-53 TB cases in 2017, incidence ranged from 1.3 in Kansas to 7.9 in New Hampshire.  Kansas, West Virginia, and Wisconsin had incidences at or below the 2020 target; no states or cities had incidences that were above the 2020 target, but were at or below the national average; Baltimore, New Mexico, Delaware, Mississippi, District of Columbia, Alaska, and New Hampshire had incidences that were above the national average of.  Among states/cities that reported 54-140 TB cases in 2017, incidence among U.S.-born non-Hispanic black or African American persons ranged from 0.5 in Indiana to 9.6 in San Francisco.  Indiana, Pennsylvania, Connecticut, Kentucky, Nevada, and Michigan had incidences at or below the 2020 target; Colorado, Oregon, Oklahoma, Missouri, and Philadelphia had incidences that were above the 2020 target, but were at or below the national average; Tennessee, South Carolina, Arkansas, Alabama, Chicago, and San Francisco had incidences that were above the national average.  Among states/cities that reported 141 or more TB cases in 2017, incidence among U.S.-born non-Hispanic black or African American persons ranged from 1.1 in Maryland to 8.2 in Houston.  Maryland, Virginia, Arizona, Ohio, New York, and Illinois had incidences at or below the 2020 target; New Jersey, North Carolina, Massachusetts, California, and New York City had incidences that were above the 2020 target, but were at or below the national average; Louisiana, Washington, Georgia, Texas, Los Angeles, Florida, San Diego, Minnesresize iconView LargerCloseThis horizontal bar graph shows individual state and city TB incidence per 100,000 U.S.-born non-Hispanic black or African American persons.  States and cities are categorized into 3 groups based on numbers of TB cases reported in 2017.  Within each group states and cities are ordered by increasing incidence and color coded by whether or not they met the 2020 national target (1.5), were between the 2020 target and national average (2.8), or had incidence above the national average.  Among states/cities that reported 1-53 TB cases in 2017, incidence ranged from 1.3 in Kansas to 7.9 in New Hampshire.  Kansas, West Virginia, and Wisconsin had incidences at or below the 2020 target; no states or cities had incidences that were above the 2020 target, but were at or below the national average; Baltimore, New Mexico, Delaware, Mississippi, District of Columbia, Alaska, and New Hampshire had incidences that were above the national average of.  Among states/cities that reported 54-140 TB cases in 2017, incidence among U.S.-born non-Hispanic black or African American persons ranged from 0.5 in Indiana to 9.6 in San Francisco.  Indiana, Pennsylvania, Connecticut, Kentucky, Nevada, and Michigan had incidences at or below the 2020 target; Colorado, Oregon, Oklahoma, Missouri, and Philadelphia had incidences that were above the 2020 target, but were at or below the national average; Tennessee, South Carolina, Arkansas, Alabama, Chicago, and San Francisco had incidences that were above the national average.  Among states/cities that reported 141 or more TB cases in 2017, incidence among U.S.-born non-Hispanic black or African American persons ranged from 1.1 in Maryland to 8.2 in Houston.  Maryland, Virginia, Arizona, Ohio, New York, and Illinois had incidences at or below the 2020 target; New Jersey, North Carolina, Massachusetts, California, and New York City had incidences that were above the 2020 target, but were at or below the national average; Louisiana, Washington, Georgia, Texas, Los Angeles, Florida, San Diego, Minnesdownload iconDownload Imageimage icon[JPG, NAN ]3Centers for Disease Control and Prevention (CDC). *Reported Tuberculosis in the United States, 2017*. Atlanta, GA: US Department of Health and Human Services, CDC; 2018.
							
					
						Page last reviewed:  March 6, 2020					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue